...
首页> 外文期刊>Advanced Biomedical Research >Effect of nebulized budesonide in preventing postextubation complications in critically patients: A prospective, randomized, double-blind, placebo-controlled study
【24h】

Effect of nebulized budesonide in preventing postextubation complications in critically patients: A prospective, randomized, double-blind, placebo-controlled study

机译:布地奈德雾化在预防危重患者拔管后并发症中的作用:一项前瞻性,随机,双盲,安慰剂对照研究

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background: The efficacy of steroid administration in the prevention of postextubation complications in critical care remains controversial. The purpose of this study was to determine whether administration of nebulized budesonide in critically ill patients reduces the occurrence of postextubation airway complications. Materials and Methods: This was a prospective, randomized, double-blind, placebo-controlled study.We prospectively followed up 70 adult patients in the intensive care unit who were intubated for more than 48 h. Patients received either nebulized budesonide (1 mg every 12 h; n = 35) or placebo (normal saline; n = 35) until 48 h after extubation. Then, the postextubation complications were assessed and recorded within 48 h of extubation. Results: The incidence of respiratory distress was lower in budesonide group (8.6% vs. 31.4%, P = 0.017). Reintubation with mechanical support was necessary in 8.6% (3.35) of patients in the budesonide group and 31.4% (11.35) of patients in the placebo group ( P = 0.017). Conclusion: Nebulized budesonide after extubation is effective in reducing the incidence of reintubation and respiratory distress in adult patients.
机译:背景:类固醇激素在重症监护中预防拔管后并发症的功效仍存在争议。这项研究的目的是确定在危重患者中使用雾化布地奈德是否可以减少拔管后气道并发症的发生。材料和方法:这是一项前瞻性,随机,双盲,安慰剂对照研究。我们对重症监护病房的70名成年患者进行了随访,随访时间超过48小时。患者在拔管后48小时之前接受雾状布地奈德(每12小时1 mg; n = 35)或安慰剂(生理盐水; n = 35)。然后,评估拔管后并发症在拔管后48小时内的记录。结果:布地奈德组呼吸窘迫的发生率较低(8.6%比31.4%,P = 0.017)。布地奈德组的患者有8.6%(3.35)需要机械支持重新插管,而安慰剂组的患者有31.4%(11.35)需要重新插管(P = 0.017)。结论:拔管后雾化布地奈德可有效降低成人患者再次插管和呼吸窘迫的发生率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号